Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq, Jozefien; Van Damme, Karel F. A.; De Leeuw, Elisabethet al.
2021 • In The Lancet Respiratory Medicine, 9 (12), p. 1427-1438
[en] BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. METHODS: We did a prospective, multicentre, open-label, randomised, controlled trial, in hospitalised patients with COVID-19, hypoxia, and signs of a cytokine release syndrome across 16 hospitals in Belgium. Eligible patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO(2):FiO(2)) of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum (either a single ferritin measurement of more than 2000 μg/L and immediately requiring high flow oxygen or mechanical ventilation, or a ferritin concentration of more than 1000 μg/L, which had been increasing over the previous 24 h, or lymphopenia below 800/mL with two of the following criteria: an increasing ferritin concentration of more than 700 μg/L, an increasing lactate dehydrogenase concentration of more than 300 international units per L, an increasing C-reactive protein concentration of more than 70 mg/L, or an increasing D-dimers concentration of more than 1000 ng/mL). The COV-AID trial has a 2 × 2 factorial design to evaluate IL-1 blockade versus no IL-1 blockade and IL-6 blockade versus no IL-6 blockade. Patients were randomly assigned by means of permuted block randomisation with varying block size and stratification by centre. In a first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or to receive no IL-1 blockade (1:2). In a second randomisation step, patients were allocated to receive a single dose of siltuximab (11 mg/kg) intravenously, or a single dose of tocilizumab (8 mg/kg) intravenously, or to receive no IL-6 blockade (1:1:1). The primary outcome was the time to clinical improvement, defined as time from randomisation to an increase of at least two points on a 6-category ordinal scale or to discharge from hospital alive. The primary and supportive efficacy endpoints were assessed in the intention-to-treat population. Safety was assessed in the safety population. This study is registered online with ClinicalTrials.gov (NCT04330638) and EudraCT (2020-001500-41) and is complete. FINDINGS: Between April 4, and Dec 6, 2020, 342 patients were randomly assigned to IL-1 blockade (n=112) or no IL-1 blockade (n=230) and simultaneously randomly assigned to IL-6 blockade (n=227; 114 for tocilizumab and 113 for siltuximab) or no IL-6 blockade (n=115). Most patients were male (265 [77%] of 342), median age was 65 years (IQR 54-73), and median Systematic Organ Failure Assessment (SOFA) score at randomisation was 3 (2-4). All 342 patients were included in the primary intention-to-treat analysis. The estimated median time to clinical improvement was 12 days (95% CI 10-16) in the IL-1 blockade group versus 12 days (10-15) in the no IL-1 blockade group (hazard ratio [HR] 0·94 [95% CI 0·73-1·21]). For the IL-6 blockade group, the estimated median time to clinical improvement was 11 days (95% CI 10-16) versus 12 days (11-16) in the no IL-6 blockade group (HR 1·00 [0·78-1·29]). 55 patients died during the study, but no evidence for differences in mortality between treatment groups was found. The incidence of serious adverse events and serious infections was similar across study groups. INTERPRETATION: Drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in this sample of patients with COVID-19, hypoxic respiratory failure, low SOFA score, and low baseline mortality risk. FUNDING: Belgian Health Care Knowledge Center and VIB Grand Challenges program.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Declercq, Jozefien
Van Damme, Karel F. A.
De Leeuw, Elisabeth
Maes, Bastiaan
Bosteels, Cedric
Tavernier, Simon J.
De Buyser, Stefanie
Colman, Roos
Hites, Maya
Verschelden, Gil
Fivez, Tom
Moerman, Filip
Demedts, Ingel K.
Dauby, Nicolas
De Schryver, Nicolas
Govaerts, Elke
Vandecasteele, Stefaan J.
Van Laethem, Johan
Anguille, Sebastien
van der Hilst, Jeroen
Misset, Benoît ; Université de Liège - ULiège > Département des sciences cliniques > Soins intensifs
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Leisman, DE, Ronner, L, Pinotti, R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 8 (2020), 1233–1244.
Giamarellos-Bourboulis, EJ, Netea, MG, Rovina, N, et al. Complex immune dysregulation in covid-19 patients with severe respiratory failure. Cell Host Microbe 27 (2020), 992–1000.e3.
Herold, T, Jurinovic, V, Arnreich, C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol, 146, 2020, 128 36.e4.
Del Valle, DM, Kim-Schulze, S, Huang, HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26 (2020), 1636–1643.
Aziz, M, Fatima, R, Assaly, R, Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol 92 (2020), 2283–2285.
Zhu, J, Pang, J, Ji, P, et al. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol 93 (2021), 35–37.
Abers, MS, Delmonte, OM, Ricotta, EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 6, 2021, 144455.
Nagant, C, Ponthieux, F, Smet, J, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis 101 (2020), 342–345.
McElvaney, OJ, McEvoy, NL, McElvaney, OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med 202 (2020), 812–821.
Horby, P, Lim, WS, Emberson, JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 384 (2021), 693–704.
Sterne, JAC, Murthy, S, Diaz, JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A. JAMA 324 (2020), 1330–1341.
Angriman, F, Ferreyro, BL, Burry, L, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med 9 (2021), 655–664.
Jones, SA, Hunter, CA, Is IL-6 a key cytokine target for therapy in COVID-19?. Nat Rev Immunol 21 (2021), 337–339.
Galván-Román, JM, Rodríguez-García, SC, Roy-Vallejo, E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 147 (2021), 72–80.e8.
Matthay, MA, Luetkemeyer, AF, IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how?. JAMA 326 (2021), 483–485.
Sinha, P, Matthay, MA, Calfee, CS, Is a “Cytokine storm” relevant to COVID-19?. JAMA Intern Med 180 (2020), 1152–1154.
Tharaux, P-L, Pialoux, G, Pavot, A, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 9 (2021), 295–304.
Kyriazopoulou, E, Poulakou, G, Milionis, H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med, 2021 published online May 18. https://doi:10.1038/s41591-021-01499-z.
Stone, JH, Frigault, MJ, Serling-Boyd, NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 383 (2020), 2333–2344.
Hermine, O, Mariette, X, Tharaux, PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 181 (2021), 32–40.
Rosas, IO, Bräu, N, Waters, M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 384 (2021), 1503–1516.
Soin, AS, Kumar, K, Choudhary, NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 9 (2021), 511–521.
Veiga, VC, Prats, JAGG, Farias, DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 372, 2021, n84.
Lescure, FX, Honda, H, Fowler, RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9 (2021), 522–532.
Salama, C, Han, J, Yau, L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 384 (2021), 20–30.
Gordon, AC, Mouncey, PR, Al-Beidh, F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 384 (2021), 1491–1502.
Wang, D, Fu, B, Peng, Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med 15 (2021), 486–494.
Salvarani, C, Dolci, G, Massari, M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 181 (2021), 24–31.
Horby, PW, Pessoa-Amorim, G, Peto, L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397 (2021), 1637–1645.
Shankar-Hari, M, Vale, CL, Godolphin, PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326 (2021), 499–518.
Dodd, LE, Freidlin, B, Korn, EL, Platform trials—beware the noncomparable control group. N Engl J Med 384 (2021), 1572–1573.
Rockwood, K, Song, X, MacKnight, C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 173 (2005), 489–495.
Maes, B, Bosteels, C, De Leeuw, E, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials, 21, 2020, 468.
Harris, PA, Taylor, R, Minor, BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform, 95, 2019, 103208.
Harris, PA, Taylor, R, Thielke, R, Payne, J, Gonzalez, N, Conde, JG, Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42 (2009), 377–381.
Cavalli, G, De Luca, G, Campochiaro, C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2 (2020), e325–e331.
Collignon, O, Burman, CF, Posch, M, Schiel, A, Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome. Clin Pharmacol Ther 110 (2021), 311–320.
Wilson, JG, Calfee, CS, ARDS Subphenotypes: understanding a heterogeneous syndrome. Crit Care, 24, 2020, 102.